Brilacidin
A nonpeptidic defensin mimetic investigated for antimicrobial and inflammatory conditions.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Investigational
Investigational; not FDA-approved for the uses discussed.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A nonpeptidic defensin mimetic investigated for antimicrobial and inflammatory conditions.
Investigational; not FDA-approved for the uses discussed.
Laboratory antiviral activity is not proof of clinical infection treatment, and a current pivotal program was not verified.
Why It's Being Studied
- Antimicrobial research
- Oral mucositis
- Inflammatory signalling
Mechanism of Action
Its membrane-active design mimics aspects of host-defense peptides, but it is not a conventional peptide.
Its membrane-active design mimics aspects of host-defense peptides, but it is not a conventional peptide. Laboratory antiviral activity is not proof of clinical infection treatment, and a current pivotal program was not verified.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Antimicrobial research
- Oral mucositis
- Inflammatory signalling
- Intravenous clinical research
- Local clinical formulations
Evidence Summary
Phase 2 human programs include skin infection and oral mucositis; the COVID-19 trial did not establish its primary clinical benefit.
Higher tiers carry more weight. Filled tiers have evidence for Brilacidin; tap to read it.
- Phase 2 human programs include skin infection and oral mucositis; the COVID-19 trial did not establish its primary clinical benefit.
1 cited sources.
- Regulatory document1
Human clinical evidence
- Phase 2 human programs include skin infection and oral mucositis; the COVID-19 trial did not establish its primary clinical benefit.
Reported Adverse Events in Research
- Systemic tolerability, small samples and indication-specific adverse effects require cautious interpretation.
Limitations of Current Evidence
- Laboratory antiviral activity is not proof of clinical infection treatment, and a current pivotal program was not verified.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Brilacidin | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Investigational | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intravenous clinical research, Local clinical formulations | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
Brilacidin — regulatory document